Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer.
Curr Opin Mol Ther
; 4(1): 49-53, 2002 Feb.
Article
en En
| MEDLINE
| ID: mdl-11883695
ABSTRACT
Disabled infectious single cycle-herpes simplex viruses (DISC-HSV) have been shown to be safe for use in humans and may be considered efficacious as vectors for immunogene therapy in cancer. Preclinical studies show that DISC-HSV is an efficient delivery system for cytokine genes and antigens. DISC-HSV infects a high proportion of cells, resulting in rapid gene expression for at least 72 h. The DISC-HSV-mGM-CSF vector, when inoculated into tumors, induces tumor regression in a high percentage of animals, concomitant with establishing a cytotoxic T-cell response, which is MHC class I restricted and directed against peptides of known tumor antigens. The inherent properties of DISC-HSV makes it a suitable vector for consideration in human immunogene therapy trials.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Simplexvirus
/
Vacunas contra el Cáncer
/
Vectores Genéticos
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Mol Ther
Asunto de la revista:
BIOLOGIA MOLECULAR
/
TERAPEUTICA
Año:
2002
Tipo del documento:
Article
País de afiliación:
Reino Unido